US Patent

US11672803 — Use of inhibitors of Brutons tyrosine kinase (Btk)

Method of Use · Assigned to Pharmacyclics LLC · Expires 2031-06-03 · 5y remaining

Vulnerability score 64/100 Moderate — design-around opportunities exist

What this patent protects

Methods for treating cancer involve administering a Btk inhibitor, determining a lymphocyte expression profile, and adjusting treatment based on that profile.

USPTO Abstract

Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2666 — Imbruvica
U-1684 — Imbruvica
U-1684 — Imbruvica
U-1684 — Imbruvica
U-2242 — Imbruvica
U-1684 — Imbruvica

Patent Metadata

Patent number
US11672803
Jurisdiction
US
Classification
Method of Use
Expires
2031-06-03
Drug substance claim
No
Drug product claim
No
Assignee
Pharmacyclics LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.